Pairwise and Network Meta-Analysis of Antiviral and other Treatment Efficacy in Covid-19 Patients
Keywords:COVID-19, treatment efficacy, Network meta-analysis, Pairwise meta-analysis, worldwide
A total of 77 literatures till November 2020 were screened regarding various interventions to treat COVID-19
patients, among which 16 and 15 studies fulfilling predefined exclusion and inclusion criteria were subjected to
Pairwise and Network meta-analysis respectively. In Pairwise meta-analysis, the recovery rate of treatment with
Lopinavir/Ritonavir versus other antiviral (OR= 0. 0381, CI= 0.0021-0.6870), placebo (OR= 0.6592, CI= 0.4207-1.
0329), Remdesivir (OR= 0.5286, CI= 0.3915-0.7137) and standard care (OR= 0.9787, CI= 0.8523-1.1238) in fixed
and random effect model with 95% confidence limit found statistically significant protection than those of all
other treatment. In Network meta-analysis, recovery estimates sizes of treatment, in reference with other antivirals
1.0000 (0.9917, 1.0000) shows less risk with treatment Standard care 0.7811 (0.6696, 0.8417), Remdesivir 0.7717
(0.6491, 0.8144), Lopinavir/ Ritonavir 0.7801 (0.6701, 0.8473), Placebo 0.7219 (0.6178, 0.7836).
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.